Americhem Unveils 2024 Sustainability Report Highlighting Major Accomplishments
5.12.2024 16:00:00 CET | Business Wire | Press release
Report Showcases Company’s Commitment to Environmental Responsibility, Highlights Future Ambitions
Americhem, Inc., a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, proudly announces the release of its 2024 Sustainability Report. This comprehensive report, titled Embracing Our Tomorrow, highlights Americhem’s unwavering commitment to environmental and social responsibility, providing an in-depth look at the company’s efforts across the entire value chain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205637181/en/
Lauren Lutikoff, Americhem Global Sustainability Leader (Photo: Business Wire)
Following the recent award of the Silver EcoVadis Medal, which places Americhem among the top 15% of companies assessed by EcoVadis—a globally recognized platform that rates businesses’ sustainability in various categories including Environment, Labor and Human Rights, Ethics, and Sustainable Procurement. Americhem’s sustainability report showcases the company’s major accomplishments and outlines future ambitions, including:
Americhem 2030 Plan: Over the past few years, Americhem has established baseline performance metrics and set targets within the business for each key pillar, aligning with the UN Sustainable Development Goals and Americhem’s vision for sustainability. The plan outlines the company’s dedication to advancing operations, developing sustainable solutions, and empowering employees, all while contributing to the communities in which it operates.
Americhem Decarbonization Strategy: The report reveals a robust decarbonization strategy focused on renewable energy, waste handling, and resource conservation projects at Americhem’s facilities. Other actions include increasing collaborative efforts with suppliers and customers to reduce greenhouse gas emissions.
“Meeting the sustainability goals of our customers requires the same mindset—embracing change while meeting the high-quality standards that consumers demand. Embarking on our sustainability journey is more than just a commitment; it’s a pledge for the future. Our mission is to lead with integrity, innovate responsibly, and inspire progress,” said John Richard, CEO at Americhem.
Major Accomplishments Built on Three Critical Pillars
Americhem’s sustainable framework is built on three critical pillars: People, Process, and Product. In 2024, Americhem rolled out programs and launched new products that contributed to these pillars, including:
People: Americhem’s commitment to world-class safety is demonstrated through its “Next Level Safety” campaign. The company has significantly surpassed industry benchmarks, with a Total Recordable Incident Rate (TRIR) 22% below the industry average.
Process: Americhem announced it is now sourcing 100% electricity through a local renewable energy program for its World Headquarters location. This transition is estimated to avoid approximately 750 metric tons of CO2 emissions annually1, equivalent to the carbon sequestered by 875 acres of U.S. forests in one year2.
Product: Americhem continues to lead in innovation with new product offerings such as the EcoLube™ line of PFAS-free internally lubricated compounds, addressing industry challenges around proposed PFAS regulations and promoting environmental responsibility.
Lauren Lutikoff, Americhem’s Global Sustainability Leader, said, “Americhem’s initiatives are aligned with the company’s commitment to innovation, while continually advancing environmental responsibility and product safety.”
“In today’s world, operating sustainably is no longer a choice, but a necessity. At Americhem, we recognize that sustainability is fundamental to our future and the well-being of our planet. This report is not just an accounting of our accomplishments, but rather a path for continued improvement and a testament of our dedication to a better tomorrow,” added Lutikoff.
To read Americhem’s sustainability report, visit www.americhem.com/pages/sustainability.
About Americhem
Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world.
1Calculation based on City of Cuyahoga Falls’ Utility Department Emissions Factor Rating for 2022 and Americhem Global Headquarters’ annual electricity consumption data.
2Calculation based on the EPA’s Greenhouse Gas Equivalency Calculator (https://www.epa.gov/energy/greenhouse-gas-equivalencies-calculator#results)
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205637181/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom